- Home
- NABL vs DNTH Comparison
NABL vs DNTH Comparison
Compare NABL & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NABL
- DNTH
- Stock Information
- Founded
- NABL 2000
- DNTH 2015
- Country
- NABL United States
- DNTH United States
- Employees
- NABL N/A
- DNTH N/A
- Industry
- NABL Computer Software: Prepackaged Software
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- NABL Technology
- DNTH Health Care
- Exchange
- NABL Nasdaq
- DNTH Nasdaq
- Market Cap
- NABL 1.5B
- DNTH 1.5B
- IPO Year
- NABL N/A
- DNTH N/A
- Fundamental
- Price
- NABL $7.60
- DNTH $35.59
- Analyst Decision
- NABL Buy
- DNTH Strong Buy
- Analyst Count
- NABL 4
- DNTH 11
- Target Price
- NABL $9.31
- DNTH $65.22
- AVG Volume (30 Days)
- NABL 745.0K
- DNTH 615.1K
- Earning Date
- NABL 11-06-2025
- DNTH 11-06-2025
- Dividend Yield
- NABL N/A
- DNTH N/A
- EPS Growth
- NABL N/A
- DNTH N/A
- EPS
- NABL 0.01
- DNTH N/A
- Revenue
- NABL $482,397,000.00
- DNTH $4,854,000.00
- Revenue This Year
- NABL $9.79
- DNTH N/A
- Revenue Next Year
- NABL $8.97
- DNTH N/A
- P/E Ratio
- NABL $741.74
- DNTH N/A
- Revenue Growth
- NABL 7.40
- DNTH 17.87
- 52 Week Low
- NABL $6.07
- DNTH $13.37
- 52 Week High
- NABL $13.04
- DNTH $40.16
- Technical
- Relative Strength Index (RSI)
- NABL 43.95
- DNTH 54.31
- Support Level
- NABL $7.51
- DNTH $33.34
- Resistance Level
- NABL $7.78
- DNTH $38.66
- Average True Range (ATR)
- NABL 0.23
- DNTH 1.97
- MACD
- NABL -0.02
- DNTH -0.49
- Stochastic Oscillator
- NABL 34.76
- DNTH 31.96
About NABL N-able Inc.
N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.